Scavenger receptor AI/II truncation, lung function and COPD: a large population-based study. 2011

M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.

OBJECTIVE The scavenger receptor A-I/II (SRA-I/II) on alveolar macrophages is involved in recognition and clearance of modified lipids and inhaled particulates. A rare variant of the SRA-I/II gene, Arg293X, truncates the distal collagen-like domain, which is essential for ligand recognition. We tested whether the Arg293X variant is associated with reduced lung function and risk of chronic obstructive pulmonary disease (COPD) in the general population. METHODS We genotyped 48,741 individuals from the adult Danish general population for Arg293X, and recorded lung function and spirometry-defined COPD. RESULTS Arg293X homozygotes (n = 5) and heterozygotes (n = 587), compared with noncarriers (n = 48,149), had a 6% and 1% reduction in predicted percentage of forced vital capacity (FVC % predicted) (P = 0.05) and a nonsignificant 7% and 1% reduction in predicted percentage of forced expiratory volume in one second (FEV(1) % predicted) (P = 0.06), respectively. The Arg293X genotype interacted with gender (P = 0.004) and α(1) -antitrypsin MZ heterozygosity (P = 0.049), but not with superoxide dismutase-3 E1I1 heterozygosity (P = 0.11) in determining FEV(1) % predicted. Amongst men, FEV(1) % predicted and FVC % predicted were both reduced by 4% (P = 0.0004 and P = 0.0003, respectively) in Arg293X heterozygotes compared with noncarriers. Corresponding values were 14% (P = 0.03) and 11% (P = 0.04) amongst MZ heterozygotes, and 9% (P = 0.03) and 8% (P = 0.04) amongst E1I1 heterozygotes, compared with noncarriers. Lung function did not differ between Arg293X heterozygotes and noncarriers amongst females or individuals without MZ and E1I1. Arg293X heterozygosity was associated with spirometry-defined COPD amongst men [odds ratio (95% confidence interval): 1.7 (1.1-2.4)], but not with COPD in the whole cohort or in any other subgroup. CONCLUSIONS SRAI/II Arg293X heterozygotes have reduced lung function and increased COPD risk amongst men. They also have reduced lung function amongst individuals heterozygous for the α(1)-antitrypsin MZ and superoxide dismutase-3 E1I1 genotypes.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003718 Denmark A country in northern Europe, bordering the Baltic Sea and the North Sea. The capital is Copenhagen. Faeroe Islands,Faroe Islands
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
February 2001, Nihon rinsho. Japanese journal of clinical medicine,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
October 2006, American journal of respiratory cell and molecular biology,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
July 2021, EClinicalMedicine,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
February 2003, Neurobiology of disease,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
July 2019, The European respiratory journal,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
December 2005, Journal of immunology (Baltimore, Md. : 1950),
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
March 2018, Respiratory medicine,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
October 2013, American journal of respiratory and critical care medicine,
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
July 2023, Current oncology (Toronto, Ont.),
M Thomsen, and B G Nordestgaard, and A Tybjaerg-Hansen, and M Dahl
January 2018, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,
Copied contents to your clipboard!